Mandate

Vinge advises Doro in connection with the acquisition of IVS

May 15, 2013

Vinge has advised Doro in connection with the acquisition of the German distributor IVS Industrievertretung Schweiger GmbH (“IVS”). The acquisition price for IVS, including the maximum additional purchase price in 2014 and 2015, amounts to EUR 17.6 million on a cash and debt free basis. The acquisition is financed through a combination of existing cash and bank loans and Doro also has an option to finance part of the acquisition with Doro shares.

Doro’s products and solutions are available in more than 30 countries spanning five continents and the product range includes mobile phones, apps and software, fixed telephony, telecare and solutions within mHealth. Doro’s turnover in 2012 was SEK 837.5 million and the company’s shares are listed on OMX Nasdaq Stockholm, Nordic List, Small-cap.

Vinge primarily advised Doro on the capital markets and corporate law issues pertaining to the acquisition. Vinge’s team consisted of responsible partner Johan Winnerblad together with associates Charlotte Levin, Matthias Pannier, Dain Nevonen and Christian Hybbinette. 

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025